Scoop has an Ethical Paywall
Work smarter with a Pro licence Learn More

Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 

Medicinal power of Kolorex Horopito extract in big demand

Medicinal power of NZ’s Kolorex Horopito extract in big demand

Press release, 19 April, 2016, Nelson, NZ:

Natural health product innovation company, Forest Herbs Research, is experiencing growing demand for its clinically proven anti-fungal products made from a single variety of New Zealand’s ancient Horopito plant.

The company owns the world’s only sustainably managed commercial plantation of 30,000 native Horopito plants on the edge of the Kahurangi National Park in Golden Bay, and is preparing a third piece of land with the aim to quadruple the number of mature plants by 2020.

At the Natural Products NZ Summit held in Nelson last month, Forest Herbs Research was recognised, together with Auckland company Phytomed Medicinal Herbs, as a joint winner of The Cawthron Institute Innovation in Science & Technology Award. The judges were impressed with the company’s excellent use of New Zealand-grown herbs, and the extensive research that was conducted, ranging from process improvements to in-clinic trials.

The natural products industry is a significant contributor to New Zealand’s economy with earnings of over $1.4 billion per annum. For over 20 years, Forest Herbs Research has been conducting R&D and clinical trials on Horopito’s therapeutic effect in collaboration with research organisations, universities, naturopaths, and distribution partners. Findings show that Horopito is a proven and effective natural treatment against numerous fungal ailments including: chronic intestinal candidiasis, vaginal thrush, and athlete’s foot.

Advertisement - scroll to continue reading

Are you getting our free newsletter?

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.

With a patent over the best method for extracting Kolorex Horopito, Forest Herbs exports and licenses Horopito products under its Kolorex®brand to companies from Europe, USA and Australia through to places as varied as Dubai, Israel and South Africa.

Horopito is a native plant of New Zealand with a long history of traditional medicinal use. The leaves were either bruised, steeped in water and used to treat skin diseases and venereal diseases, or they were chewed to relieve toothache. After twenty years researching the properties of this plant, Forest Herbs Research found one specific high potency cultivar of with up to five times the potency of all other Horopito populations. The team then spent several years of further R&D to work out how to grow the plant sustainably.

Dr Amanda Wiggins, Business Development Manager at Forest Herbs Research says, “Research and development has been a core contributor to our ongoing success. The positive results of clinical trials on our Kolorex Horopito extract give us enormous credibility, and we have attracted a number of new business customers as a result - including a large multi-national pharmaceutical company that is now selling Kolorex® in South Africa. We’re also getting a lot of enquiries from consumers in the Asian market and, with help from NZ Trade and Enterprise, we’re actively seeking distribution partners in China.”

NZ Forest Herbs founder, Peter Butler, says it is the efficacy of Kolorex products rather than NZ's clean green image that is driving demand. “Our distributors are looking for products that are scientifically formulated, batch tested and carry some supporting clinical data.

“The natural personal care industry is also an increasing market, with strong evidence that growing consumer awareness of synthetic chemicals in cosmetics and toiletries, and the desire for truly natural products, are propelling a 10% year on year growth in the industry.”

Researchers expect the global organic personal care market to reach USD 15.98 billion by 2020.

“We’re about to launch a new hygiene product in a few weeks, which we are really excited about, and we will continue to research and develop new products,” says Butler.


ends

© Scoop Media

Advertisement - scroll to continue reading
 
 
 
Business Headlines | Sci-Tech Headlines

 
GenPro: General Practices Begin Issuing Clause 14 Notices

GenPro has been copied into a rising number of Clause 14 notices issued since the NZNO lodged its Primary Practice Pay Equity Claim against General Practice employers in December 2023.More

SPADA: Screen Industry Unites For Streaming Platform Regulation & Intellectual Property Protections

In an unprecedented international collaboration, representatives of screen producing organisations from around the world have released a joint statement.More

 
 
 
 
 
 
 
 
 
 
 
 

Join Our Free Newsletter

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.